End of 2025/26 RSV Prevention Program for Infants and High-Risk Children                                       

The Ministry of Health has announced the conclusion of the 2025/26 Respiratory Syncytial Virus (RSV) Prevention Program for maternal, infant, and high-risk pediatric populations, effective April 17, 2026.

 

As of this date, the RSV prevention program for infants, pregnant individuals, and high-risk children has officially ended for the season, and preventive products for these groups should no longer be administered.

 

The older adult RSV prevention program will continue through the spring and summer months, as the vaccine provides multi-year protection with a single dose and does not require a booster at this time.

 

Health care providers should continue administering the RSV vaccine to eligible older adults and order vaccines using the RSV order form available on the website. Providers should not administer doses of Beyfortus (monoclonal antibody) to infants or children, or Abrysvo (maternal RSV vaccine) to pregnant individuals after April 17.

 

All remaining non-expired RSV inventory should be stored at your premises under appropriate cold chain conditions for use during the next RSV season.

 

We appreciate the ongoing dedication of health care providers in supporting RSV prevention efforts across the community.

 

For questions or further information, please contact the Public Health Vaccine Preventable Disease Program at 519-575-4400 ext. 5505.